Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: Slovenian real-world data

Adjuvant nivolumab has become the new standard of care for patients with oesophageal and gastroesophageal junction cancer (OEC/GEJC) following neoadjuvant chemoradiotherapy (neoCRT) and surgical resection. In Slovenia, this treatment has been in use since January 2022. Here, we report the first Slov...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Hribernik Nezka, Arko Rozala, Gasljevic Gorana, Rebersek Martina
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Sciendo 2026-04-01
Ráidu:	Radiology and Oncology
Fáttát:	oesophageal and gastroesophageal junction cancer adjuvant immunotherapy nivolumab
Liŋkkat:	https://doi.org/10.2478/raon-2026-0020
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!